Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.
Telix has assembled a portfolio of molecularly targeted radiation therapeutic and imaging products for kidney, prostate and brain cancers. Each product has been validated by clinical studies or compassionate use, reducing development risk. It acquired its JV partner ANMI in December, giving it full global rights to the TLX591-CDx investigational prostate cancer imaging kit. It is commercialising TLX591-CDx (illumet) in the US and Europe, and anticipates filing for US approval in 2019. It expects to fully enrol the ZIRCON confirmatory Phase III for kidney cancer imaging agent TLX250-CDx by end 2019. Preliminary data from the IPAX-1 Phase I/II study of TLX101 therapy in GBM (brain cancer) is expected in Q319. Telix plans to progress TLX591 therapy into Phase III in chemo-naive prostate cancer in H219/H120. A trial of TLX250 in kidney cancer is expected to commence mid-2019.
Big pharma has shown keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US$3.9bn. In 2014 Bayer acquired Algeta for ~US$2.6bn; Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. In December Novartis acquired prostate cancer radiopharmaceutical developer Endocyte for US$2.1bn.